Cipla’s Avenue Receives Second CRL For Intravenous Tramadol

As Company Continues To Pursue FDA Approval For The Painkiller

 
• By Akriti Seth
  
Generate a summary of this article
Listen to this article
Beta

Cipla’s Avenue Therapeutics has received a second complete response letter from the US FDA regarding its new drug application for an intravenous formulation of tramadol. The company has disagreed with the FDA’s observations and said that it will continue to pursue regulatory approval for IV tramadol.

Arm Wrestle
Avenue and FDA lock horns over the regulatory approval of IV tramadol • Source: Alamy

Cipla’s Avenue Therapeutics Inc. has received a second complete response letter from the US Food and Drug Administration regarding its 505(b)(2) new drug application for its intravenous formulation of painkiller, IV tramadol. However, Avenue said that it disagrees with the FDA’s interpretation of the data in the NDA and intends to continue to pursue regulatory approval for IV tramadol.

Focused on the development of intravenous tramadol for the US market, Avenue noted that IV tramadol is a potential alternative...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Value Added Medicines

Neuraxpharm Enters Japanese Market 1

 
• By David Wallace

Neuraxpharm has expanded its footprint outside of Europe with the launch of its first product in Japan, in the form of the Buccolam value-added midazolam product gained through a deal with Takeda.

Hyloris Sets Out Plans To Expand Its Pipeline

 
• By Akriti Seth

After partnering with companies like Purna Female Healthcare and AFT Pharmaceuticals, Belgian value-added medicines specialist Hyloris has announced plans to add three new products to its pipeline in the coming months with a goal of having 14 commercial products by 2024. 

Awards Offers Two Weeks Of Online Networking

 
• By David Wallace

From 20 October, a free online platform will allow registrants attending the digital Global Generics & Biosimilars Awards 2020 to participate in two weeks of dedicated networking activities ahead of the ceremony on 3 November.

Hyloris And Purna Strike Value-Added Development Deal

 
• By David Wallace

Value-added medicines specialist Hyloris has struck a deal worth up to €4.3m with Purna Female Healthcare to develop a treatment for vulvovaginal candidiasis that combines miconazole and domiphen bromide.

More from Products

For Generics, A Victory Lap – And A Warning – On Drug Shortages

Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

Biocon And Teva Sign Up To Biosimilars Forum

Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.